The SNP, rs11672691, resides in an active enhancer element and the risk G allele increases the chromatin binding of HOXA2, which subsequently promotes the expression of PCAT19 and CEACAM21 (Figure 1C), which may contribute to the aggressive phenotype of prostate cancer [68]. The gene discussed is CEACAM21; the disease is prostate carcinoma.